These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17273726)

  • 1. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients.
    Materna V; Surowiak P; Markwitz E; Spaczynski M; Drag-Zalesinska M; Zabel M; Lage H
    Oncol Rep; 2007 Mar; 17(3):505-16. PubMed ID: 17273726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of DNA mismatch repair protein hMSH2 immunohistochemistry with p53 and apoptosis in cervical carcinoma.
    Köster F; Schröer A; Fischer D; Greweldinger T; Diedrich K; Friedrich M
    Anticancer Res; 2007; 27(1A):63-8. PubMed ID: 17352217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
    Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
    Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry of proteins for DNA mismatch repair in correlation to prognostic factors of mammarian cancer.
    Köster F; Schröer A; Fischer D; Horn AK; Diedrich K; Friedrich M
    Oncol Rep; 2007 May; 17(5):1223-7. PubMed ID: 17390069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
    Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
    Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
    Branch P; Masson M; Aquilina G; Bignami M; Karran P
    Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair and treatment resistance in ovarian cancer.
    Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
    BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.
    Smyth EF; Sharma A; Sivarajasingham N; Hartley J; Monson JR; Cawkwell L
    Dis Colon Rectum; 2004 Dec; 47(12):2086-91; discussion 2091-2. PubMed ID: 15657659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients.
    Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
    Cancer Lett; 2007 Jul; 252(1):131-46. PubMed ID: 17276589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma.
    Tzao C; Hsu HS; Sun GH; Lai HL; Wang YC; Tung HJ; Yu CP; Cheng YL; Lee SC
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1371. PubMed ID: 16256791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer.
    Kitajima Y; Miyazaki K; Matsukura S; Tanaka M; Sekiguchi M
    Gastric Cancer; 2003; 6(2):86-95. PubMed ID: 12861399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.
    Aquilina G; Ceccotti S; Martinelli S; Soddu S; Crescenzi M; Branch P; Karran P; Bignami M
    Clin Cancer Res; 2000 Feb; 6(2):671-80. PubMed ID: 10690553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
    Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
    Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
    Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival with an intact DNA mismatch repair system in endometrial cancer.
    Cohn DE; Frankel WL; Resnick KE; Zanagnolo VL; Copeland LJ; Hampel H; Kelbick N; Morrison CD; Fowler JM
    Obstet Gynecol; 2006 Nov; 108(5):1208-15. PubMed ID: 17077244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
    Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
    Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
    Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.